Device helps doctors select lungs for transplant

(HealthDay)—The Xvivo Perfusion System has been approved by the U.S. Food and Drug Administration to help doctors determine whether lungs are suitable for transplant, the agency said in a news release.

The device can temporarily ventilate, oxygenate and pump preservation solution through the lungs, allowing a transplant team to conduct a more thorough assessment of function.

The device was given limited approval in 2014, curtailing its use to a maximum of 8,000 patients per year, the agency said. The new approval removes that and other restrictions.

Lung transplant remains the only approved treatment for advanced lung disease, and many people die while waiting for donor lungs to become available. On average, 15 percent of donor lungs are suitable for transplant, the FDA said. About 2,530 lung transplants were performed last year, U.S. government statistics show.

The device's most common adverse reactions included bronchial complications, and infections.

The product is produced by the Swedish company Xvivo Perfusion Inc.


Explore further

FDA approves lung preservation machine (Update)

More information: The FDA has more about this approval.

Copyright © 2019 HealthDay. All rights reserved.

Citation: Device helps doctors select lungs for transplant (2019, April 29) retrieved 13 October 2019 from https://medicalxpress.com/news/2019-04-device-doctors-lungs-transplant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more